SecBot SecBot

BNGO

Bionano Genomics, Inc.
Nasdaq· Laboratory Analytical Instruments· Inc. DE· CIK 0001411690 Genomics & Gene Editing
$1.16 +0.03 (+2.65%)
Oct 26 4:00 PM ET · prev $1.13
Market cap
$13.9M
Nano cap
Median target
$5.00
+331% · range $4.00–6.00
Next earnings
Nov 11
in 15 days · EPS est. −$0.45
1 year
−39.3%
from $1.91 · Oct 27
30 days
−31.0%
from $1.68
52-week range
$1.06–1.91
−39% from high · low Jul 30
Avg volume 20D
268.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$9.7K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 2 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/4 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Orin Hirschman and affiliated entities (AIGH Capital Management LLC, AIGH Investment Partners LLC) filed a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $9.7K at an average $1.21. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.540 → −$0.450 over 90 days. 1 up, 0 down in 30 days.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM89,993$101.7K
UBS Group AGDOUBLED812$918.00
CITIGROUP INCDOUBLED3$3.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED167,533$196.0K
RENAISSANCE TECHNOLOGIES LLCADD48,700$57.0K
GROUP ONE TRADING LLCTRIM957$1.1K
MORGAN STANLEYTRIM927$1.1K
WELLS FARGO & COMPANY/MNDOUBLED113$132.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +331%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Apr 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 24, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 18, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 20, 2025Maxim Group
UPGRADE
UPGRADEBuy
Apr 9, 2025HC Wainwright & Co.
INITIATE
INITIATEBuy
Apr 2, 2025Scotiabank
MAINTAIN
MAINTAINSector Perform

Insider ledger

Form 4
$9.7K
bought · 1 insider
$0
sold · 0 insiders
−4.4%
vs their $1.21 cost
DateInsiderTypeValue
Sep 4, 2026
Luderer Albert
Interim Chief Executive
BUY$4.8K
Aug 21, 2026
Luderer Albert
Interim Chief Executive
BUY$4.9K
Aug 3, 2026
Adamchak Mark
Principal Accounting Officer
AWARD5,000 sh
Aug 3, 2026
Hastie Alex Reid
Chief Scientific Officer
AWARD54,000 sh
Aug 3, 2026
Dixon Jonathan V.
General Counsel
AWARD15,000 sh
Aug 3, 2026
OLDAKOWSKI MARK
Chief Operating Officer
AWARD15,000 sh
Jun 3, 2026
Adamchak Mark
Principal Accounting Officer
TAX W/H$9.10
Jun 3, 2026
Chaubey Alka
CHIEF MEDICAL OFFICER
TAX W/H$31.20

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.45
EPS estimate, this quarter
+17%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.45-$0.45–-$0.45-7.1%$8.4M
Next Q-$0.39-$0.39–-$0.39+2.5%$9.3M
Current FY-$2.14-$2.14–-$2.14-0.5%$32.1M
Next FY-$0.97-$0.97–-$0.97+0.0%$43.3M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Orin Hirschman and affiliated entities (AIGH Capital Management LLC, AIGH Investment Partners LLC) filed a new…
SC 13G — Impact 4/10
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Sep 14, 2026 Press
Bionano Genomics highlighted three new peer-reviewed publications demonstrating that its optical genome mapping (OGM)…
Impact 5/10
Sep 14, 2026 SEC
Bionano Genomics presented an investor deck at the H.C. Wainwright conference, highlighting Q2 2026 revenue of $8.2M…
8-K — Impact 6/10
Sep 4, 2026 Insider
Luderer Albert bought 4,000 shares
Interim Chief Executive @ $1.21 ($4.8K)
Aug 21, 2026 Insider
Luderer Albert bought 4,000 shares
Interim Chief Executive @ $1.22 ($4.9K)
Aug 10, 2026 SEC
Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31%…
8-K — Impact 5/10
Aug 3, 2026 Insider
Adamchak Mark was granted 5,000 shares
Principal Accounting Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
BNGO Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Sep 30, 2026
Short interest
Short Interest: BNGO up 78% to 2.0M shares
Settlement 2026-09-30 | Days to cover: 2.08 | ≈17.28% of shares outstanding (est.)
Sep 14, 2026
FDA
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute report that…
Aug 10, 2026
Earnings date
BNGO Q2 2026 Earnings Scheduled — 2026-08-10
Jul 27, 2026
Earnings
Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live…

SecBot reports

5 filings · 2 press releases · 2 bullish · 1 bearish · 1 mixed · 1 neutral
All BNGO filing & press-release reports (7)